UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 57

Sortiert nach

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy

Nature communications, 2021-01, Vol.12 (1), p.352-352, Article 352

2021

Volltextzugriff (PDF)

Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling

Nature communications, 2021-03, Vol.12 (1), p.1858-1858, Article 1858

2021

Volltextzugriff (PDF)

EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma

PloS one, 2014-04, Vol.9 (4), p.e94281-e94281

2014

Volltextzugriff (PDF)

Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas

Archives of pathology & laboratory medicine (1976), 2017-12, Vol.141 (12), p.1697-1704

2017

Volltextzugriff (PDF)

An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

Molecular cancer therapeutics, 2009-10, Vol.8 (10), p.2773-2779

2009

Volltextzugriff (PDF)

Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function

Clinical cancer research, 2007-04, Vol.13 (7), p.2158-2167

2007

Volltextzugriff (PDF)

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma

PloS one, 2012-02, Vol.7 (2), p.e31046-e31046

2012

Volltextzugriff (PDF)

Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma

Journal for immunotherapy of cancer, 2021-04, Vol.9 (4), p.e002203

2021

Volltextzugriff (PDF)

Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice

PloS one, 2013-03, Vol.8 (3), p.e59082

2013

Volltextzugriff (PDF)

EGFRvIII-Targeted Vaccination Therapy of Malignant Glioma

Brain pathology (Zurich, Switzerland), 2009-10, Vol.19 (4), p.713-723

2009

Volltextzugriff (PDF)

Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations

Journal for immunotherapy of cancer, 2019-05, Vol.7 (1), p.142-14, Article 142

2019

Volltextzugriff (PDF)

Recurrent Glioblastoma Treated with Recombinant Poliovirus

The New England journal of medicine, 2018-07, Vol.379 (2), p.150-161

2018

Volltextzugriff (PDF)

Intratumor childhood vaccine-specific CD4+ T-cell recall coordinates antitumor CD8+ T cells and eosinophils

Journal for immunotherapy of cancer, 2023-04, Vol.11 (4), p.e006463

2023

Volltextzugriff (PDF)

Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma

Journal for immunotherapy of cancer, 2022-09, Vol.10 (9), p.e005052

2022

Volltextzugriff (PDF)

Immunotoxin Therapy for Lung Cancer

Chinese medical journal, 2017-03, Vol.130 (5), p.607-612

2017

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor VIII Peptide Vaccination Is Efficacious against Established Intracerebral Tumors

Clinical cancer research, 2003-09, Vol.9 (11), p.4247-4254

2003

Volltextzugriff (PDF)

MRP3: a molecular target for human glioblastoma multiforme immunotherapy

BMC cancer, 2010-09, Vol.10 (1), p.468-468, Article 468

2010

Volltextzugriff (PDF)

Polio virotherapy targets the malignant glioma myeloid infiltrate with diffuse microglia activation engulfing the CNS

Neuro-oncology (Charlottesville, Va.), 2023-09, Vol.25 (9), p.1631-1643

2023

Volltextzugriff (PDF)

A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma

Clinical cancer research, 2018-08, Vol.24 (15), p.3611-3631

2018

Volltextzugriff (PDF)

Oncolytic polio virotherapy of cancer

Cancer, 2014-11, Vol.120 (21), p.3277-3286

2014

Volltextzugriff (PDF)

Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma

Journal of clinical neuroscience, 2014-01, Vol.21 (1), p.189-190

2014

Volltextzugriff (PDF)

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma

Seminars in immunology, 2008-10, Vol.20 (5), p.267-275

2008

Volltextzugriff (PDF)

Efficacy of Intracerebral Microinfusion of Trastuzumab in an Athymic Rat Model of Intracerebral Metastatic Breast Cancer

Clinical cancer research, 2003-11, Vol.9 (15), p.5514-5520

2003

Volltextzugriff (PDF)

Recombinant polio–rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial

The lancet child & adolescent health, 2023-07, Vol.7 (7), p.471-478

2023

Volltextzugriff (PDF)

Bispecific antibodies engage T cells for antitumor immunotherapy

Expert opinion on biological therapy, 2011-07, Vol.11 (7), p.843-853

2011

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Aktive Filter

KollektionAmerican Association for the Advancement of Science

Zeitschrift / SerieCancer Research

ThemaTumors Of The Nervous System. Phacomatoses

ThemaImmunotherapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(54)

Publikationsform

Artikel
(56)
Buchkapitel
(1)

Sprache

Englisch
(57)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy

Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling

EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma

Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas

An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function

A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma

Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma

Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice

EGFRvIII-Targeted Vaccination Therapy of Malignant Glioma

Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations

Recurrent Glioblastoma Treated with Recombinant Poliovirus

Intratumor childhood vaccine-specific CD4+ T-cell recall coordinates antitumor CD8+ T cells and eosinophils

Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma

Immunotoxin Therapy for Lung Cancer

Epidermal Growth Factor Receptor VIII Peptide Vaccination Is Efficacious against Established Intracerebral Tumors

MRP3: a molecular target for human glioblastoma multiforme immunotherapy

Polio virotherapy targets the malignant glioma myeloid infiltrate with diffuse microglia activation engulfing the CNS

A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma

Oncolytic polio virotherapy of cancer

Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma

Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma

Efficacy of Intracerebral Microinfusion of Trastuzumab in an Athymic Rat Model of Intracerebral Metastatic Breast Cancer

Recombinant polio–rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial

Bispecific antibodies engage T cells for antitumor immunotherapy

Aktive Filter

Suchergebnisse filtern